Porton USA
About Porton USA
Categories
![Porton USA](/Porton%20logo4_8_2024-comp305945.jpg)
-
US
-
2022On CPHI since
-
5000+Employees
Company types
Porton USA Resources (2)
-
Webinar Co-processing: A Multifaceted Approach for Enhancing Density & Powder Flow
Discover the Power of Co-processing: Unleashing the Potential of Pharmaceutical Manufacturing. Our multifaceted co-processing technology is a game-changer, boosting density, optimizing powder flow, ensuring content uniformity, and enhancing solubility-dissolution. But that's not all – it also goes above and beyond, safeguarding your workforce from potent Active Pharmaceutical Ingredients (APIs). Embrace innovation and efficiency with our cutting-edge co-processing solutions and elevate your pharmaceutical production to new heights. Experience the future of manufacturing! Understand the potential of co-processing technology - what are the key benefits over existing solutions? Discover how the industry is embracing co-processing technology Learn some of the common techniques on the co-processing technology platform See examples of how co-processing can improve powder flow and density, and improve formulation rigidity -
Webinar Chiral Resolution by Salt/Cocrystal Formation
Most of the drug molecules are chiral compounds with enantiomers. Each enantiomer may show significant differences in biological activities, such as pharmacodynamics, pharmacokinetics and toxicity. It is therefore recommended to market chiral drugs containing only the desired enantiomer. It is thus critical to develop a production process that leads to enantiopure dug substance. In this context, chiral resolution has become a crucial step in pharmaceutical development and crystallization-based resolutions are widely utilized to produce enantiopure drug substance of high purity. This presentation will review the concept of conglomerate, racemic compound and solid solution as well as how to differentiate them using phase diagrams and analytical techniques. It will discuss chiral resolution methods though salt and cocrystal formation followed by crystallization using a couple of case studies. One case study was to identify a cocrystal conglomerate followed by development of a chiral resolution process based on preferred crystallization. The other case study is to perform classic chiral resolution by diastereomeric salt formation which is considered one of the most effective methods for production of chirally pure drugs at large scale. Understand why classical resolution by salt formation is often considered as one of the most efficient methods to produce enantiopure pharmaceuticals on a large scale strategically design a rational approach to a solid form screening study Optimize a crystallization process to be scaled up to various scales
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance